This is a best-case Phase 3 readout for a first-in-class in vivo CRISPR therapy. Traders should expect a significant positive gap on open. Key catalysts ahead: BLA acceptance, FDA advisory committee, and potential early approval. Monitor for any safety signals in longer-term follow-up and competitive dynamics from existing HAE prophylactics (Takhzyro, Orladeyo).
Price Chart
Executive Summary
Intellia reported additional positive Phase 3 HAELO results for lonvo-z (CRISPR gene editing candidate) in hereditary angioedema, with 87% attack reduction (p<0.0001), 62% attack-free rate, and favorable safety. Rolling BLA submission is underway with anticipated U.S. approval and launch in H1 2027. This is a transformative clinical milestone for the first in vivo CRISPR therapy.
Key Facts
- Phase 3 HAELO trial met primary endpoint: 87% reduction in mean monthly attacks vs placebo (p<0.0001) during weeks 5-28
- 62% of lonvo-z patients were entirely attack-free and therapy-free for 6 months vs 11% placebo (p<0.0001)
- 89% reduction in attacks requiring on-demand treatment (p<0.0001); 91% reduction in moderate/severe attacks (p<0.0001)
- AE-QoL quality of life score improved by -17.04 points vs placebo (p<0.0001), far exceeding the 6-point clinically important threshold
- No serious adverse events in the lonvo-z arm; all TEAEs were mild or moderate
- Rolling BLA submission initiated in April 2026; company anticipates regulatory approval and U.S. launch in first half of 2027
- Data presented at EAACI 2026 and simultaneously published in the New England Journal of Medicine
Financial Impact
No financial data in filing; pre-revenue company. If approved, lonvo-z targets a ~$5B+ global HAE market with potential to become first one-time curative treatment.
Risk Factors
- Regulatory risk: FDA may request additional data or impose REMS
- Commercial risk: lonvo-z requires IV infusion; competition from oral and subcutaneous prophylactics
- Manufacturing and reimbursement challenges for a one-time gene editing therapy
- Long-term durability and safety data still limited to ~1 year follow-up
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-270358 |
| Document: ntla-ex99_1.htm | 0001193125-26-270358 |
| Document: 0001193125-26-270358-index-headers.html | 0001193125-26-270358 |
| Document: 0001193125-26-270358-index.html | 0001193125-26-270358 |
| Document: 0001193125-26-270358.txt | 0001193125-26-270358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers